EPICENTRX, INC.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.epicentrx.com
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
- Conditions
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT02489903
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Baptist Health, Lexington, Kentucky, United States
🇺🇸Memorial Hospital of South Bend, South Bend, Indiana, United States
RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02452970
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT02215512
- Locations
- 🇺🇸
The Cancer Institute of New Jersey (Rutgers University), New Brunswick, New Jersey, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Allegiance Health, Jackson, Michigan, United States
A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT02096341
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT02096354
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸Kaiser Permanete, Honolulu, Hawaii, United States
🇺🇸Stanford University, Stanford, California, United States
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01359982
- Locations
- 🇺🇸
Moores University of California San Diego Cancer Center, La Jolla, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States